Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Appointed CFO
|
|
GILEAD SCIENCES, INC. (GILD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/07/2020 |
GN
| Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology |
| 09/14/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout |
| 09/01/2020 |
GN
| Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program |
| 12/11/2019 |
GN
| Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma |
| 05/31/2019 |
GN
| Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| 12/10/2018 |
GN
| New Research Coverage Highlights Skyworks Solutions, Virtus Investment Partners, Altria Group, Gilead Sciences, Arthur J. Gallagher, and BP p.l.c — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 04/17/2018 |
GN
| New Research Coverage Highlights DexCom, Equinix, Fitbit, Gilead Sciences, Humana, and Microsoft — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 02/01/2018 |
GN
| Market Trends Toward New Normal in Alexander's, Atrion, FS, Gilead Sciences, Abbott Laboratories, and Johnson & Johnson — Emerging Consolidated Expectations, Analyst Ratings |
| 12/07/2017 |
GN
| Gilead Sciences to Acquire Cell Design Labs |
| 11/28/2017 |
GN
| Analysis: Positioning to Benefit within Garmin, J P Morgan Chase, Gilead Sciences, Windstream, Cardinal Health, and QEP Resources — Research Highlights Growth, Revenue, and Consolidated Results |
|
|